{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '10.4', 'Health Authorities', 'The protocol and any applicable documentation (subject information and consent form) will be', 'submitted or notified to the National Health Authorities in accordance with the regulations of the', 'country or countries involved in the study.', '11', 'Management and Reporting of Adverse Events', 'Safety of Rebif will mainly be evaluated by the recording of all AEs.', '11.1', 'Adverse Events', 'Adverse Event', 'An AE is any untoward medical occurrence in a patient or clinical study subject administered a', 'pharmaceutical product and which does not necessarily have a causal relationship with this', 'treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal', 'laboratory finding), symptom, or disease temporally associated with the use of a medicinal', 'product, whether or not considered related to the medicinal product.', 'Adverse Reaction', 'An AR is a response to a medicinal product which is noxious and unintended.', 'Response in this context means that a causal relationship between a medicinal product and an AE', 'is at least a reasonable possibility.', 'ARs may arise from use of the product within or outside the terms of the marketing authorisation', 'or from occupational exposure. Conditions of use outside the marketing authorisation include', 'off-label use, overdose, misuse, abuse and medication errors.', 'Serious Adverse Event/Serious Adverse Reaction', 'A SAE/reaction is any AE/AR as defined above, which also fulfills at least one of the', 'seriousness criteria below:', 'Results in death', 'Is life-threatening\u00b9', 'Requires in-patient hospitalization or prolongation of existing hospitalization', 'Results in persistent or significant disability/incapacity', 'Is a congenital anomaly/birth defect', 'Is otherwise considered as medically important\u00b2', 'CONFIDENTIAL', '37/60', 'INFORMATION', 'M']['Interferon beta-1a', 'MESTRE-MS Study', 'EMR200136_597', 'PLife-threatening in this context refers to a reaction in which the patient was at risk of death', 'at the time of the reaction; it does not refer to a reaction that hypothetically might have', 'caused death if more severe.', '2) Medical and scientific judgement should be exercised in deciding whether other situations', 'should be considered serious reactions, such as important medical events that might not be', 'immediately life threatening or result in death or hospitalisation but might jeopardise the', 'patient or might require intervention to prevent one of the other outcomes listed above.', 'Examples of such events are intensive treatment in an emergency room or at home for', 'allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation', 'or development of dependency or abuse.', 'Any suspected transmission via a medicinal product of an infectious agent is also considered a', 'serious AR.', 'Events not to be considered as AEs', 'Medical conditions present at study start, that do not worsen in severity or frequency during the', 'study are defined as Baseline medical conditions, and are NOT to be considered AEs.', '11.2', 'Severity of Adverse Events', 'Investigators should assess the severity/intensity of any AEs as follows:', 'Mild:', 'The subject is aware of the event or symptom, but the event or symptom is', 'easily tolerated.', 'Moderate:', 'The subject experiences sufficient discomfort to interfere with or reduce his or', 'her usual level of activity.', 'Severe:', 'Significant impairment of functioning: the subject is unable to carry out usual', 'activities.', '11.3', 'Causality Assessment', 'Investigators must assess the causal relationship between AEs and study drug (including any', 'other non-medicinal product, radiation therapy, etc.) considering temporal relationship between', 'the AE onset and study drug administration, safety profile of study drug (known side effects), the', \"patient's condition (medical history, underlying disease), concomitant medication, and study\", 'procedures.', 'Related:', 'Suspected to be reasonably related to any study medication.', 'Not related: Not suspected to be reasonably related to any study medication. A reasonable', 'alternative explanation must be available.', 'CONFIDENTIAL', '38/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '11.4', 'Recording of Adverse Events in the Case Report Form', 'The recording period for AEs begins, when the subject is initially included in the study (date of', 'signature of first informed consent) and continues until the End of the Study (Visit 3 or', 'premature withdrawal).', 'All SAEs (related and not related) and non SAEs (related AEs) must be collected in the eCRF.', 'Each AE, as specified above, occurring during the study, must be documented by the', 'Investigator within 24 hours of awareness and must be recorded in the eCRF, including its', 'description, severity, duration (onset and resolution dates), causal relationship (i.e., confirmation', 'that the AR is suspected to be reasonably related to the study treatment), any other potential', 'causal factors, actions taken with the study drug (dose reduction, withdrawal), required', 'treatment, and outcome. In addition, for all serious ARs, seriousness criteria must be documented', 'and a specific safety report form must be completed and sent to the Sponsor, as described below', 'Death, disability, and hospitalization are considered outcomes in the context of safety reporting', 'and not usually considered ARs/AEs. Therefore the primary cause of death, disability or', 'hospitalization should be recorded and reported as an SAE/AR, and the outcome should be', 'recorded in a separate data field. However, a term for the outcome will be selected if it is the', 'only information reported or provides significant clinical information.', 'If death occurs, the primary cause of death or event leading to death should be recorded and', 'reported as an SAE. \"Fatal\" will be recorded as the OUTCOME of this respective event and not', 'be as separate event. Only, if no cause of death can be reported (for example, sudden death,', 'unexplained death), the death per se might then be reported as an SAE.', 'Medication Errors, Overdose, Abuse, and Misuse', 'Events of medication errors, overdose, abuse and misuse of study drug are also to be recorded in', 'the eCRF, even if occurring without AE.', 'Pregnancy and Lactation', 'If encountered on this study exposure to study drug during pregnancy or lactation is to be', 'recorded in the eCRF and to be reported to the study sponsor.', '11.5', 'Safety Reporting to the Study Sponsor', 'Safety data collection forms:', 'The following safety data collection forms are used in this study:', 'SAE Report Form', 'Pregnancy Report Form', 'Parent-Child/Foetus AE Report Form', 'CONFIDENTIAI', '39/60', 'INFORMATION', 'M']\n\n###\n\n", "completion": "END"}